GlassScriptPhysician profile
Jill Salyards
NPI 1972868438
$3,832.78
in general payments reported to CMS, 2019-2025
28 companies · $22.43 in 2025
The $22.43 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,196 · 2020: $796 · 2021: $421 · 2022: $569 · 2023: $752 · 2024: $76.99 · 2025: $22.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $836 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $835.96 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $633.25 | 2019-2023 | Taltz, Olumiant |
| Ucb, INC. | $435.59 | 2019-2024 | Cimzia, Bimzelx |
| Abbvie INC. | $433.45 | 2019-2023 | Skyrizi |
| Novartis Pharmaceuticals Corporation | $373.81 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $292.57 | 2019-2023 | Dupixent |
| Pfizer INC. | $254.16 | 2019-2024 | |
| Janssen Biotech, INC. | $168.95 | 2019-2021 | |
| Genentech USA, INC. | $165.79 | 2019-2021 | |
| Epi Health, LLC | $138.91 | 2019-2022 | |
| Genzyme Corporation | $137.96 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $119.95 | 2019-2023 | Jublia, Arazlo |
| Mayne Pharma Commercial LLC | $116.96 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $94.01 | 2019-2023 | Absorica Ld, Winlevi |
| Leo Pharma INC. | $91.86 | 2019-2025 | Adbry |
| Almirall LLC | $64.33 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $51.99 | 2020-2023 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $42.40 | 2022-2023 | Sotyktu |
| Vyne Pharmaceuticals INC. | $36.10 | 2020 | |
| Galderma Laboratories, L.P. | $29.11 | 2019-2020 | |
| Biofrontera INC. | $20.94 | 2019 | |
| Encore Dermatology INC. | $19.05 | 2019 | |
| Incyte Corporation | $18.60 | 2022 | |
| Dermavant Sciences, INC. | $17.92 | 2023 | Vtama |
| Promius Pharma LLC | $17.21 | 2019 | |
| Celgene Corporation | $16.45 | 2019 | |
| Dusa Pharmaceuticals, INC. | $15.38 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.41 | 2019 | |
| Merck Sharp & Dohme LLC | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Salyards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.